{Reference Type}: Journal Article
{Title}: Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause.
{Author}: Palacios S;González SP;Sánchez-Prieto M;Fasero M;
{Journal}: Expert Opin Pharmacother
{Volume}: 25
{Issue}: 10
{Year}: 2024 Jul 27
{Factor}: 4.103
{DOI}: 10.1080/14656566.2024.2383639
{Abstract}: <B>UNASSIGNED: </B>Osteoporosis is a chronic systemic skeletal disorder characterized by compromised bone strength and an increased risk of fracture, with a high prevalence worldwide. It is associated with a negative quality of life and an increased morbidity and mortality. Postmenopausal women are more prone to develop osteoporosis, and many of them will suffer at least one fragility fracture along their lifetime.<BR><B>UNASSIGNED: </B>This review starts by summarizing the pathogenesis of postmenopausal osteoporosis (PMO), with focus on the estrogen deficiency-associated bone loss. It continues with the current PMO diagnostic and fracture risk prediction tools, and it finally addresses management of PMO. All the efficacy and safety profiles of the current and future osteoporosis medications are reviewed. Furthermore, strategies to optimize the long-term disease management are discussed. For this review, only publications in English language were selected. References were extracted from PubMed, Embase, and Medline.<BR><B>UNASSIGNED: </B>PMO disease management is far from being ideal. Educational and communication programs with the goal of improving disease knowledge and awareness, as well as reducing the health-care gap, should be implemented. In addition, most effective sequential prevention and treatment strategies should be initiated from the early menopause.